Filing summary
Issuer mismatch: The filing provided is Graphite Bio, Inc.’s Form 10-Q for the quarter ended June 30, 2023, not a filing for LENZ Therapeutics, Inc. The summary below reflects Graphite Bio’s filing.
Business context and reporting period
Graphite Bio was a clinical-stage gene-editing company with no product revenue. After a serious adverse event in the first patient dosed in its Phase 1/2 CEDAR study, the company paused the study in January 2023 and discontinued development of its lead sickle cell disease candidate, nula-cel, in February. It began exploring strategic alternatives and substantially reduced its workforce. The unaudited filing reports the three and six months ended June 30, 2023, compared with the corresponding 2022 periods.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $13.5 million | $17.8 million |
| General and administrative expense | $7.5 million | $9.0 million |
| Restructuring and impairment costs | $37.2 million | None |
| Net loss | $55.3 million | $25.9 million |
| Net loss per share, basic and diluted | $0.97 | $0.48 |
- For the six months ended June 30, 2023, net loss was $79.2 million versus $51.8 million in 2022. Operating expenses totaled $84.6 million versus $52.7 million.
- Cash, cash equivalents and marketable securities totaled $246.7 million at June 30, 2023, down from $283.6 million at December 31, 2022. Cash and cash equivalents were $128.5 million; current marketable securities were $118.2 million.
- Six-month operating cash use was $34.7 million, compared with $43.3 million in 2022. Investing activities provided $115.4 million, mainly reflecting maturities of marketable securities; financing activities provided $0.1 million.
- Current assets were $251.2 million and current liabilities were $12.3 million. The filing reports no borrowings or other financial debt; lease liabilities were $53.5 million, including $50.6 million non-current. There are no meaningful product-sales margins to report.
Material changes, outlook and risks
- Year-over-year quarterly R&D expense fell $4.3 million, mainly from lower clinical-trial, manufacturing and personnel costs; G&A fell $1.5 million. These savings were more than offset by restructuring and impairment charges.
- Restructuring and impairment costs included a $35.0 million non-cash impairment related to the Bayside facility lease, $1.1 million for lab equipment held for sale and severance costs. The company plans to sublease the facility but remains responsible for rent until it finds a subtenant or replacement tenant. Remaining undiscounted lease payments were $88.4 million.
- Management stated that available cash, cash equivalents and marketable securities were expected to fund the current operating plan for at least 12 months from issuance of the financial statements; the MD&A estimated funding into the fourth quarter of 2024. Both are estimates, not guarantees.
- In August 2023, after quarter-end, the company sold its non-genotoxic conditioning assets for upfront and contingent consideration of up to approximately $1.5 million, plus other potential payments. It also licensed nula-cel and related platform assets and granted an option to acquire them in return for a 20% fully diluted equity interest in the counterparty; exercise depends on the counterparty meeting a financing milestone. The company continued to explore strategic alternatives.
- Key risks include uncertainty about the strategic-alternatives process and future operations, the discontinued lead program, the ability to sublease the facility, and the need for additional capital if plans or cash needs change. The company reported no material change to the risk factors in its 2022 Form 10-K and no material legal proceedings.
Important facts for investors to verify
- Confirm the issuer: this source is Graphite Bio’s filing, despite the request metadata naming LENZ Therapeutics.
- Review the status and terms of the August 2023 asset sale and license-and-option transaction, including contingent payments, the financing milestone and the counterparty equity interest.
- Assess the cash runway assumptions against ongoing losses, the strategic plan and any future financing needs.
- Track sublease progress and potential further impairment or lease-related costs for the Bayside facility.
- Reconcile the filing’s differing runway descriptions: at least 12 months from financial-statement issuance and into Q4 2024 in the MD&A.